TLDR:
- AION Labs, a venture studio specializing in AI-driven drug discovery, has formed a strategic partnership with Amiti Ventures, an Israeli early-stage venture capital firm.
- The partnership will help accelerate Israel’s position as a leading hub for transformative AI-powered drug discovery innovation.
AION Labs, a venture studio focused on using AI technologies and computational science for drug discovery, has partnered with Amiti Ventures, an Israeli venture capital firm.
The partnership aims to strengthen the alliance between AION Labs and global leaders in the pharmaceutical, biotech, and technology investment sectors. It will also enhance AION Labs’ expertise in deep tech and computational technology domains, which are crucial for biotech innovation.
Amiti Ventures will bring its experience and knowledge in deep tech and computational biology to support AION Labs’ early-stage startups focused on AI and computational biology in drug discovery and development.
Amiti Ventures’ first investment in AION Labs will be in DenovAI Biotech’s seed round of funding. DenovAI is developing an AI-powered biophysics solution for de novo antibody and protein design.
The partnership with Amiti Ventures will further support AION Labs’ mission to advance precision medicine and contribute to the healthcare industry by bringing new treatments to market faster and more efficiently.
AION Labs aims to bridge the gap between academic research in AI and the pharmaceutical industry, leveraging Israel’s startup ecosystem and expertise to develop innovative technologies for drug discovery and development.
The partnership with Amiti Ventures is expected to drive transformative AI-powered drug discovery innovation in Israel and position the country as a leading hub in this field.
